CNS Pharmaceuticals, Inc.

2100 West Loop South, Suite 900

Houston, TX 77027

May 15, 2024

VIA EDGAR

U.S. Securities and Exchange Commission

Division of Corporate Finance

Washington, DC 20549

Attention: Lauren Hamill

	Re:	CNS Pharmaceuticals, Inc.
		Registration Statement on Form S-3
		Registration No. 333-279285

Ladies and Gentlemen:

Pursuant to Rule 461 of the Securities Act of 1933, as amended, CNS Pharmaceuticals, Inc., a Nevada corporation (the “Company”), hereby respectfully requests that the effective date for the Registration Statement referred to above be accelerated so that it will be declared effective at 4:00 P.M. (Eastern Time) on May 17, 2024, or as soon thereafter as possible on such date.

	Very truly yours,

	CNS Pharmaceuticals, Inc.


	By:	/s/ Christopher Downs
		Name: Christopher Downs
		Title: Chief Financial Officer